Quantcast

Latest Erythropoietin Stories

2010-09-28 08:00:00

EXTON, Pa., Sept. 28 /PRNewswire/ -- BioTrends Research Group, Inc. recently published its TreatmentTrends®: The Role of Anemia Managers, Practice Managers and Facility Administrators in the Management of Renal Anemia report, based on online survey results from approximately 150 anemia managers and qualitative interviews with over 35 practice managers and facility administrators. These stakeholders are an important part of the renal anemia care team and are responsible for...

2010-09-27 06:30:00

NES-ZIONA, Israel, Sept. 27 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that data from its longer-acting human growth hormone (hGH-CTP) program will be featured in an oral scientific presentation at the 5th International Congress Of The Growth Hormone Research Society (GRS) and IGF Society on October 4, 2010. PROLOR is developing hGH-CTP to provide growth hormone-deficient adults and children...

2010-08-24 06:30:00

NES-ZIONA, Israel, Aug. 24 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to conduct a Phase II clinical trial in the U.S. of its longer-acting version of human growth hormone, hGH-CTP. The regulatory clearance followed PROLOR's submission of an Investigational New Drug (IND) application for...

2010-08-04 15:28:00

Bio-Gal is Developing a Drug for the Treatment of Multiple Myeloma ("MM") Patients - Research and Clinical Observations of MM Terminal Patients by Bio-Gal Suggests That Treatment with Erythropoietin Suppresses the Disease, Prolonging and Improving the Patients' Lives. - XTL is Commencing Preparations to Begin a Phase 2 Clinical Trial in Multiple Myeloma Patients - Under the Transaction, XTL Received $1.5 Million in Cash XTL has announced that their...

2010-07-26 09:34:00

LAKE FOREST, Ill., July 26 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy. The...

2010-07-26 07:00:00

EXTON, Pa., July 26 /PRNewswire/ -- BioTrends Research Group, Inc. recently published its TreatmentTrends®: US Nephrology Q2 2010 report. This quarterly report series is based on online survey results from over 100 Nephrologists and captures physician attitudes, perceptions and self-reported behavior with a focus on renal anemia and bone and mineral metabolism. In the renal anemia market, the use of erythropoietin stimulating agents (ESAs) in patients with chronic...

2010-07-16 17:32:00

LOS ANGELES, July 16 /PRNewswire/ -- Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as...

2010-06-29 06:30:00

NES-ZIONA, Israel, June 29 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that it has received formal Good Manufacturing Practice (GMP) certification for hGH-CTP, the company's proprietary biobetter version of human growth hormone. GMP certification is required by the European Union (EU) clinical trials legislation as a precondition for conducting clinical trials in EU member countries....

2010-06-22 10:56:00

HARRISBURG, Pa., June 22 /PRNewswire-USNewswire/ -- The Pennsylvania Horse Racing Commission will begin testing thoroughbred race horses for total carbon dioxide, or TCO2, after approving a policy to conduct the testing at its meeting on June 17. The commission first voted to implement TCO2 testing during its March meeting. Since that time, commission staff worked to develop the policy, which strictly prohibits the use of agents or substances that elevate a horse's TCO2 level beyond what...

2010-06-01 06:30:00

NES-ZIONA, Israel, June 1 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that Chief Executive Officer Avri Havron and President Shai Novik will ring the opening bell at the New York Stock Exchange (NYSE) at 9:30 AM ET on Thursday, June 3, 2010. "It is a privilege to celebrate PROLOR's recent listing on the NYSE Amex by ringing the opening bell at the New York Stock...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related